previou
studi
peripher
blood
lineag
cell
imc
appear
sever
burn
patient
character
inhibitor
cell
product
bdefensin
hbd
human
epiderm
keratinocyt
nhek
studi
effect
glycyrrhizin
pseudomon
skin
infect
studi
chimera
model
thermal
injuri
two
differ
chimera
model
util
patient
chimera
creat
murin
antimicrobi
peptidedeplet
nodscid
null
mice
graft
unburn
skin
tissu
sever
burn
patient
inocul
patient
peripher
blood
imc
patient
chimera
substitut
creat
mice
graft
nhek
inocul
experiment
induc
imc
result
group
chimera
treat
glycyrrhizin
resist
ld
dose
p
aeruginosa
skin
infect
chimera
group
treat
salin
die
within
day
infect
human
antimicrobi
peptid
detect
graft
site
tissu
group
chimera
treat
glycyrrhizin
peptid
detect
area
tissu
control
produc
keratinocyt
transwellcultur
perform
imc
glycyrrhizin
also
inhibitor
product
keratinocyt
detect
cultur
patient
imc
treat
glycyrrhizin
result
indic
sepsi
stem
pseudomon
graft
site
infect
chimera
model
burn
injuri
control
glycyrrhizin
impair
antimicrobi
peptid
product
infect
site
sever
burn
patient
may
restor
treatment
glycyrrhizin
pseudomona
aeruginosa
burn
wound
infect
frequent
develop
sepsi
sever
burn
patient
initi
effector
host
antibacteri
innat
immun
antimicrobi
peptid
distribut
skin
tissu
contribut
control
surfac
wound
infect
sever
burn
patient
howev
suffici
amount
antimicrobi
peptid
produc
tissu
surround
burn
site
lack
antimicrobi
peptid
product
lead
invas
pathogen
surfac
infect
system
infect
accompani
paper
lineag
cell
design
imc
isol
peripher
blood
sever
burn
patient
patient
imc
shown
inhibitori
hbd
product
normal
human
epiderm
keratinocyt
nhek
lineag
cell
isol
healthi
donor
peripher
blood
shown
noninhibitori
peptid
product
nhek
cell
character
lineag
cell
lineag
cell
isol
healthi
donor
peripher
blood
releas
patient
imc
identifi
inhibitori
factor
hbd
product
nhek
previous
report
glycyrrhizin
protect
sever
burn
mice
lethal
dose
p
aeruginosa
burn
wound
infect
test
benefic
glycyrrhizin
clinic
set
studi
antipseudomon
effect
glycyrrhizin
investig
human
model
sever
burn
injuri
combin
pseudomon
skin
infect
addit
effect
glycyrrhizin
suppressor
cell
activ
patient
imc
product
investig
graft
site
tissu
chimera
human
model
sever
burn
injuri
cirradi
nodscid
null
mice
graft
unburn
skin
tissu
sever
burn
patient
inocul
syngen
peripher
blood
imc
patient
chimera
graft
cultur
nhek
inocul
experiment
induc
imc
patient
chimera
substitut
experiment
induc
imc
isol
peripher
blood
healthi
volunt
hour
intens
exercis
treadmil
continu
hour
previous
describ
cell
shown
transient
appear
intens
exercis
heart
rate
baselin
beat
per
minut
one
continu
hour
first
appear
hour
exercis
peak
hour
exercis
disappear
glycyrrhizin
compon
licoric
root
clinic
util
patient
peptic
ulcer
chronic
hepat
cirrhosi
glycyrrhizin
report
stimul
variou
host
defens
immun
includ
inhibit
inflammatori
respons
augment
natur
killer
cell
activ
induct
variou
type
solubl
factor
ifnc
immunocompet
cell
immunomodul
activ
glycyrrhizin
inhibit
growth
hepat
viru
human
cytomegaloviru
herp
simplex
viru
influenza
viru
hiv
coronaviru
candida
albican
year
glycyrrhizin
use
clinic
treat
infecti
hepat
japan
result
present
herein
antimicrobi
peptid
produc
significantli
graft
site
skin
tissu
patient
chimera
peptid
produc
chimera
treat
glycyrrhizin
compound
directli
stimul
product
mrna
express
epiderm
keratinocyt
sepsi
stem
p
aeruginosa
skin
infect
develop
patient
chimera
patient
chimera
substitut
treat
salin
group
chimera
treat
glycyrrhizin
resist
infect
glycyrrhizin
may
benefici
pseudomon
burn
wound
infect
subsequ
sepsi
sever
burn
patient
anim
experi
perform
accord
protocol
approv
institut
anim
care
use
committe
univers
texa
medic
branch
galveston
tx
iacuc
approv
number
studi
approv
institut
review
board
univers
texa
medic
branch
irb
approv
number
written
inform
consent
blood
sampl
obtain
adult
subject
blood
sampl
children
written
parent
consent
obtain
ethic
approv
obtain
ethic
scientif
committe
univers
texa
medic
branch
nineto
male
nodscid
mice
nodcgprkdc
scid
szj
mice
purchas
jackson
laboratori
bar
harbor
usa
use
studi
accord
recent
inform
obtain
jackson
laboratori
http
nsgpdf
util
mice
mice
defici
innat
adopt
immun
without
function
cell
b
cell
nk
cell
also
mice
carrier
defect
function
phagocytosi
digest
antigen
present
activ
macrophag
use
experi
mice
expos
whole
bodi
cirradi
gy
deplet
neutrophil
bone
marrow
cell
peripher
blood
cell
taken
mice
test
morpholog
residu
neutrophil
wrightgiemsa
alkalin
phosphatas
stain
result
neutrophil
recov
mice
day
cirradi
even
stimul
pathogen
cirradi
mice
hous
anim
facil
fed
autoclav
food
water
avoid
infecti
complic
eighteen
burn
patient
male
femal
admit
shriner
hospit
children
galveston
univers
texa
medic
branch
utmb
enrol
studi
patient
total
bodi
surfac
area
tbsa
figur
import
skin
antimicrobi
peptid
resist
variou
chimera
p
aeruginosa
id
infect
cirradi
nodscid
mice
treat
mous
b
without
antimurin
amp
rabbit
igg
mous
id
infect
ld
p
aeruginosa
chimera
mous
b
graft
nhek
chimera
b
chimera
inocul
experiment
induc
imc
patient
chimera
substitut
id
infect
ld
p
aeruginosa
skin
surround
graft
site
tissu
chimera
mous
b
graft
nhek
chimera
c
chimera
inocul
lineag
cell
id
infect
p
aeruginosa
fashion
surviv
observ
week
infect
addit
antimicrobi
peptid
product
graft
site
tissu
group
chimera
test
one
day
igg
treatment
day
graft
biopsi
skin
tissu
obtain
graft
site
tissu
obtain
homogen
togeth
amount
homogen
measur
elisa
infect
experi
perform
group
mice
repeat
time
result
obtain
combin
display
figur
burn
averag
youngest
oldest
age
year
old
averag
respect
patient
subject
standard
treatment
regimen
regimen
consist
fluid
resuscit
topic
antimicrobi
agent
aggress
nutrit
support
base
estim
energi
protein
need
reagent
media
cell
kit
purchas
peprotech
rocki
hill
nj
usa
antibodi
purchas
alpha
diagnost
intern
san
antonio
tx
usa
lineag
cell
deplet
kit
purchas
miltenyi
biotec
auburn
ca
usa
fitcconjug
mab
peconjug
mab
purchas
bd
bioscienc
franklin
lake
nj
usa
biolegend
san
diego
ca
usa
respect
recombin
r
obtain
peprotech
mab
direct
purchas
biolegend
adult
normal
human
epiderm
keratinocyt
nhek
obtain
lonza
walkersvil
md
usa
propag
serumfre
keratinocyt
growth
medium
lonza
nhek
underw
second
passag
store
liquid
nitrogen
nhek
grown
store
cell
third
passag
use
studi
medium
supplement
fb
mm
lglutamin
antibiot
uml
penicillin
mgml
streptomycin
use
cultur
media
lineag
cell
proteas
inhibitor
cocktail
purchas
sigmaaldrich
st
loui
mo
usa
glycyrrhizin
glycyrrhizin
glucopyranourasylad
glucopyrano
acid
triterpenoid
saponin
glychyrrhiza
glabra
licoric
pure
glycyrrhizin
acid
ammonium
salt
glycyrrhizin
prepar
extract
licoric
root
suppli
minophagen
pharmaceut
co
ltd
tokyo
japan
glycyrrhizin
convert
glychyrrhet
acid
glycaronidas
inject
anim
patient
glycyrrhet
acid
activ
form
glycyrrhizin
variou
immunomodul
antiinflammatori
action
glycyrrhizin
util
experi
mg
compound
first
dissolv
ml
salin
serum
free
rpmi
medium
room
temperatur
mgml
dilut
appropri
concentr
salin
serum
free
rpmi
medium
store
util
base
previou
data
mgml
concentr
glycyrrhizin
ad
tissu
cultur
mgkg
dose
compound
administ
chimera
concentr
glycyrrhizin
confirm
nontox
mani
paper
prepar
imc
lineag
cell
patient
imc
prepar
peripher
mononuclear
cell
sever
burn
patient
previous
describ
larg
number
imc
obtain
sever
burn
patient
cell
experiment
figur
product
patient
chimera
treat
glycyrrhizin
patient
chimera
creat
burn
patient
unburn
skin
tissu
imc
treat
ip
glycyrrhizin
mgkg
hour
imc
inocul
control
chimera
treat
salin
mlmous
twentyfour
hour
final
glycyrrhizin
treatment
skin
biopsi
obtain
graft
site
tissu
homogen
togeth
assay
elisa
white
bar
show
result
obtain
group
mice
graft
skin
alon
recoveri
product
patient
chimera
treat
glycyrrhizin
chimera
creat
unburn
skin
tissu
patient
imc
treat
twice
mgkg
glycyrrhizin
control
chimera
treat
salin
mlmous
twentyfour
hour
treatment
skin
biopsi
obtain
graft
site
tissu
homogen
togeth
assay
elisa
white
bar
show
result
obtain
group
mice
graft
skin
alon
mean
sem
independ
experi
vs
salinetr
control
gener
healthi
donor
peripher
blood
cell
util
chimera
experi
set
experiment
condit
determin
surviv
effect
glycyrrhizin
p
aeruginosa
infect
thu
experiment
induc
imc
prepar
peripher
blood
healthi
volunt
heart
rate
baselin
beat
per
minut
subject
intens
exercis
treadmil
cybex
intern
medway
usa
heartrat
consist
kept
elev
beat
per
minut
metabol
equival
one
continu
hour
result
exercis
program
lineag
cell
first
appear
hour
exercis
peak
hour
exercis
disappear
therefor
lineag
cell
isol
peripher
blood
healthi
volunt
hour
intens
exercis
hour
util
experiment
induc
imc
experiment
induc
imc
patient
imc
shown
ident
properti
produc
inhibit
product
nhek
prepar
chimera
cirradi
nodscid
mice
graft
unburn
skin
tissu
remov
burn
patient
discard
skin
autograft
surgeri
function
discard
skin
tissu
produc
demonstr
prepar
patient
chimera
anesthet
layer
dorsal
skin
tissu
cirradi
nodscid
rc
mice
cut
cm
fold
back
expos
subcutan
layer
unburn
skin
cm
implant
singl
layer
expos
area
surgic
close
absorb
sutur
dexon
prepar
patient
chimera
substitut
cirradi
nodscid
mice
intraderm
inocul
nhek
cellsmous
six
hour
later
mice
intraderm
inocul
cell
mous
imc
surround
graft
site
detect
tissu
surround
inocul
site
group
chimera
without
imc
inocul
day
nhek
day
skin
tissu
graft
assay
imc
activ
vitro
assay
two
seri
vitro
assay
perform
determin
antiimc
activ
glycyrrhizin
transwellcultur
unburn
skin
tissu
cm
cultur
patient
imc
upper
chamber
dualchamb
transwel
supplement
mgml
glycyrrhizin
fortyeight
hour
cultiv
cultur
fluid
harvest
assay
elisa
also
cell
lower
chamber
analyz
mrna
rtpcr
previous
describ
b
condit
medium
patient
imc
cellsml
pretreat
glycyrrhizin
mgml
hour
cultur
hour
condit
media
harvest
assay
activ
inhibit
product
unburn
skin
imc
expos
pathogen
treat
glycyrrhizin
mgkg
salin
mlmous
control
two
day
infect
growth
p
aeruginosa
kidney
chimera
measur
standard
coloni
count
method
white
bar
show
result
obtain
group
mice
graft
skin
alon
condit
media
obtain
ad
unburn
skin
cm
cultur
vv
cellsml
hour
cultur
fluid
harvest
assay
elisa
vivo
assay
effect
glycyrrhizin
product
patient
chimera
patient
chimera
substitut
test
glycyrrhizin
administ
ip
chimera
hour
graft
peptideproduc
cell
five
punch
biopsi
randomli
excis
per
chimera
graft
site
skin
tissu
use
steril
biopsi
punch
mm
diamet
sklar
instrument
west
chester
pa
usa
depth
skin
biopsi
extend
way
skelet
muscl
back
epiderm
dermal
panniculu
carnosu
compon
excis
tissu
weigh
rins
cold
steril
pb
contain
antibiot
mixtur
penicillin
uml
streptomycin
sulicoriceh
mgml
min
tissu
homogen
ml
cold
pb
supplement
proteinas
inhibitor
cocktail
homogen
centrifug
g
min
supernat
homogen
assay
elisa
confirm
experi
homogen
assay
elisa
graft
site
infect
p
aeruginosa
chimera
p
aeruginosa
strain
american
type
cultur
collect
manassa
va
usa
use
studi
p
aeruginosa
grown
brainheart
infus
broth
hour
one
day
skin
infect
group
chimera
treat
sc
unit
igg
prepar
antimurin
skin
antimicrobi
peptid
amp
murin
amp
detect
skin
homogen
either
group
chimera
treat
igg
prepar
antimurin
skin
amp
rabbit
igg
purifi
sera
rabbit
immun
murin
skin
homogen
freund
complet
adjuv
describ
previous
antibodi
titer
igg
measur
neutral
activ
recombin
murin
bdefensin
one
unit
igg
titer
inactiv
mg
igg
shown
activ
neutral
activ
activ
human
bdefensin
neutral
igg
igg
treatment
cirradi
nodscid
mice
shown
suscept
die
cfumous
p
aeruginosa
intraderm
id
infect
mice
treat
salin
surviv
infect
cfumous
p
aeruginosa
fig
fact
cfumous
p
aeruginosa
infect
shown
ld
cirradi
nodscid
mice
treat
igg
cfumous
p
aeruginosa
id
infect
shown
ld
mice
treat
igg
fig
determin
protect
effect
glycyrrhizin
p
aeruginosa
id
infect
patient
chimera
patient
chimera
substitut
previous
treat
antimurin
skin
amp
rabbit
igg
see
util
throughout
infect
experi
two
day
imc
inocul
ml
p
aeruginosa
correspond
ld
sever
inject
id
graft
skin
site
chimera
effect
glycyrrhizin
evalu
decreas
mortal
rate
patient
chimera
substitut
ii
growth
pathogen
kidney
patient
chimera
kidney
infect
patient
chimera
weigh
disrupt
omni
tissu
homogen
ml
pb
number
bacteria
homogen
measur
standard
colonycount
method
express
per
gram
organ
determin
percentag
surviv
infect
mice
monitor
twice
day
sign
diseas
typic
includ
piloerect
hunch
gait
lethargi
eye
discharg
surviv
infect
mice
record
day
infect
infect
mice
display
sever
sign
distress
quantit
assess
pain
distress
chart
score
decreas
bodi
temperatur
bodi
weight
loss
labor
breath
nonrespons
cage
tap
failur
groom
sever
eye
discharg
human
euthan
ketamin
mgkg
ip
xylazin
mgkg
ip
death
assur
cervic
disloc
death
record
infect
induc
mortal
statist
analys
data
shown
figur
deriv
three
independ
experi
use
differ
donor
data
present
mean
sem
surviv
curv
analyz
use
kaplanmei
method
chimera
group
statist
compar
use
student
test
pvalu
less
result
consid
signific
import
bdefensin
host
resist
p
aeruginosa
id
infect
report
accompani
paper
lineag
cell
imc
appear
peripher
blood
sever
burn
patient
shown
respons
inhibit
product
nhek
first
seri
experi
studi
role
skin
antimicrobi
peptid
resist
mice
p
aeruginosa
id
infect
subsequ
sepsi
confirm
cirradi
nodscid
mice
deplet
murin
skin
antimicrobi
peptid
cirradi
nodscid
mice
lack
function
immunocompet
cell
includ
cell
b
cell
nk
cell
neutrophil
macrophag
result
mice
deplet
murin
skin
antimicrobi
peptid
mous
b
die
infect
cfumous
p
aeruginosa
mice
peptid
mous
surviv
even
though
expos
infect
fig
also
murin
antimicrobi
peptid
detect
skin
homogen
cirradi
nodscid
mice
peptid
detect
mice
treat
antimurin
amp
rabbit
igg
human
antimicrobi
peptid
detect
skin
homogen
cirradi
nodscid
mice
treat
without
igg
fig
next
experi
mice
deplet
murin
peptid
graft
nhek
cellsmous
id
inocul
experiment
induc
imc
graft
site
tissu
mice
infect
cfumous
p
aeruginosa
graft
site
tissu
mortal
rate
observ
result
chimera
creat
nhek
alon
chimera
surviv
p
aeruginosa
id
infect
howev
chimera
creat
nhek
graft
experiment
induc
imc
inocul
chimera
b
die
within
day
infect
fig
chimera
b
without
infect
p
aeruginosa
surviv
week
detect
homogen
graft
site
tissu
chimera
detect
graft
site
skin
homogen
chimera
b
fig
result
indic
host
antibacteri
resist
chimera
creat
nhek
p
aeruginosa
id
infect
complet
inhibit
experiment
induc
imc
chimera
c
creat
healthi
donor
lineag
cell
shown
resist
cfumous
p
aeruginosa
id
infect
fig
shown
chimera
c
amount
produc
chimera
influenc
healthi
donor
peripher
blood
lineag
cell
fig
indic
lineag
cell
suppress
product
result
shown
fig
indic
skin
antimicrobi
peptid
murin
peptid
b
c
human
peptid
import
resist
mice
p
aeruginosa
id
infect
imc
respons
inhibit
product
skin
tissu
patient
chimera
creat
unburn
skin
tissu
patient
respect
imc
treat
twice
hour
imc
inocul
ip
glycyrrhizin
one
day
final
treatment
skin
biopsi
obtain
chimera
skin
graft
site
homogen
togeth
ml
pb
assay
elisa
figur
effect
glycyrrhizin
product
patient
imc
b
product
patient
imc
cultur
supplement
glycyrrhizin
patient
imc
cellsml
cultur
presenc
absenc
glycyrrhizin
mgml
hour
cell
wash
media
cultur
addit
hour
cultur
fluid
harvest
assay
elisa
vs
control
c
effect
glycyrrhizin
number
cell
cultur
patient
imc
cultur
patient
imc
treat
glycyrrhizin
mg
ml
hour
number
cell
cultur
determin
elispot
assay
vs
control
result
detect
skin
sampl
patient
chimera
howev
peptid
detect
chimera
treat
mgkg
glycyrrhizin
level
produc
cirradi
nodscid
mice
graft
patient
unburn
tissu
fig
patient
chimera
treat
mgkg
glycyrrhizin
mgml
detect
skin
homogen
impair
peptid
product
patient
chimera
influenc
mgkg
dose
glycyrrhizin
treatment
fig
resist
chimera
treat
glycyrrhizin
p
aeruginosa
id
infect
treatment
without
glycyrrhizin
mgkg
ip
twice
surviv
patient
chimera
substitut
id
infect
ld
p
aeruginosa
test
shown
fig
chimera
treat
salin
die
within
day
infect
chimera
treat
glycyrrhizin
surviv
day
infect
antipseudomon
effect
glycyrrhizin
examin
patient
chimera
patient
chimera
creat
unburn
skin
tissu
patient
imc
infect
id
ld
p
aeruginosa
graft
site
day
imc
inocul
treat
ip
mgkg
glycyrrhizin
salin
hour
imc
inocul
two
day
infect
kidney
remov
chimera
homogen
ml
pb
number
bacteria
homogen
measur
standard
coloni
count
method
shown
fig
bacteria
grew
kidney
patient
chimera
infect
p
aeruginosa
howev
pathogen
detect
significantli
kidney
chimera
treat
glycyrrhizin
effect
glycyrrhizin
suppressor
cell
activ
patient
imc
product
patient
unburn
skin
tissu
examin
vitro
imc
cellsml
upper
chamber
burn
patient
transwellcultur
unburn
skin
tissu
cm
lower
chamber
cultur
media
supplement
without
mgml
glycyrrhizin
fortyeight
hour
cultiv
skin
tissu
lower
chamber
analyz
mrna
rtpcr
result
obtain
shown
fig
mrna
express
unburn
skin
tissu
patient
skin
transwellcultur
patient
imc
howev
mrna
express
skin
tissu
display
transwellcultur
perform
mgml
glycyrrhizin
similar
result
obtain
experi
repeat
util
unburn
patient
skin
tissu
patient
addit
amount
cultur
fluid
obtain
transwellcultur
measur
elisa
product
unburn
skin
tissu
burn
patient
inhibit
transwellcultur
patient
imc
howev
produc
transwellcultur
perform
mgml
glycyrrhizin
fig
result
shown
fig
mrna
express
protein
product
indic
produc
patient
unburn
skin
tissu
transwellcultur
perform
patient
imc
glycyrrhizin
accompani
paper
cultur
fluid
patient
imc
vv
shown
inhibitori
product
nhek
therefor
cultur
fluid
harvest
cultur
patient
imc
previous
treat
glycyrrhizin
test
inhibitori
activ
product
patient
unburn
skin
tissu
product
inhibit
vv
cultur
fluid
ad
cultur
patient
unburn
skin
tissu
cultur
fluid
obtain
patient
imc
previous
treat
glycyrrhizin
suppressor
activ
cultur
fluid
demonstr
similar
result
obtain
experi
perform
imc
patient
result
shown
fig
display
averag
product
accompani
paper
releas
patient
imc
shown
effector
molecul
inhibit
product
nhek
therefor
follow
studi
effect
glycyrrhizin
product
patient
imc
examin
thu
patient
imc
cultur
without
mg
ml
glycyrrhizin
hour
cell
wash
media
cultur
addit
hour
cultur
fluid
harvest
assay
elisa
result
signific
amount
detect
cultur
fluid
patient
imc
treat
glycyrrhizin
solubl
factor
detect
cultur
patient
imc
treat
glycyrrhizin
similar
result
obtain
experi
perform
imc
patient
fig
addit
number
cell
patient
imc
prepar
treat
without
glycyrrhizin
enumer
use
elispot
assay
averag
cell
per
imc
count
imc
prepar
patient
wherea
averag
cell
detect
imc
prepar
treat
glycyrrhizin
fig
sever
burn
patient
decreas
host
antibacteri
defens
highli
suscept
variou
infect
antibiot
effect
topic
wound
infect
subsequ
develop
sepsi
sever
burn
patient
howev
antibiot
chemotherapi
often
encourag
abnorm
microflora
multiantibioticresist
bacteri
gener
therefor
new
paradigm
treat
opportunist
burn
wound
infect
urgent
sever
burn
patient
murin
studi
p
aeruginosa
burn
wound
infect
subsequ
sepsi
immunolog
control
glycyrrhizin
suggest
glycyrrhizin
therapi
may
new
paradigm
treat
sever
burn
patient
p
aeruginosa
burn
wound
infect
establish
antipseudomon
efficaci
glycyrrhizin
clinic
set
paper
protect
effect
glycyrrhizin
sepsi
stem
p
aeruginosa
skin
infect
studi
chimera
model
sever
burn
patient
experi
perform
cirradi
nodscid
null
mice
graft
unburn
skin
tissu
discard
small
piec
skin
util
autograft
surgeri
sever
burn
patient
syngen
peripher
blood
imc
patient
chimera
also
one
part
infect
experi
patient
chimera
substitut
cirradi
nodscid
null
mice
graft
cultur
nhek
experiment
induc
imc
util
suffici
number
burn
patient
peripher
blood
imc
avail
immunolog
similar
patient
chimera
patient
chimera
substitut
demonstr
impair
product
human
skin
antimicrobi
peptid
ii
increas
suscept
p
aeruginosa
id
infect
iii
remark
product
human
effector
factor
patient
imc
inhibit
antimicrobi
peptid
product
base
previou
studi
glycyrrhizin
administ
ip
chimera
dose
mgkg
greatest
efficaci
glycyrrhizin
recov
product
seen
chimera
treat
mgkg
dose
glycyrrhizin
protect
effect
glycyrrhizin
graft
site
p
aeruginosa
id
infect
examin
patient
chimera
previous
elimin
murin
skin
antimicrobi
peptid
syngen
experiment
system
may
display
accur
antibacteri
respons
shown
sever
burn
patient
p
aeruginosa
burn
wound
infect
infect
p
aeruginosa
graft
site
bacteria
grew
kidney
chimera
bacteria
detect
kidney
chimera
treat
glycyrrhizin
result
indic
sepsi
stem
graft
site
p
aeruginosa
infect
develop
patient
chimera
treat
glycyrrhizin
effect
glycyrrhizin
surviv
patient
chimera
substitut
id
infect
lethal
dose
p
aeruginosa
also
test
result
chimera
treat
salin
die
within
day
infect
chimera
treat
glycyrrhizin
surviv
day
infect
result
obtain
chimera
studi
strongli
indic
glycyrrhizin
benefici
treat
pseudomon
burn
wound
infect
subsequ
sepsi
sever
burn
patient
current
intraven
dose
glycyrrhizin
mgday
clinic
util
patient
chronic
hepat
individu
treat
high
dose
glycyrrhizin
mg
experi
advers
effect
hypermineralocorticoid
sodium
retent
potassium
loss
edema
increas
blood
pressur
depress
renninangiotensinaldosteron
system
advers
effect
due
hydrolysi
glycyrrhizin
intestin
pharmacolog
activ
compound
glycyrrhet
acid
inhibit
enzym
betahydroxysteroid
dehydrogenas
involv
metabol
corticosteroid
inhibit
enzym
lead
increas
cortisol
level
kidney
studi
howev
nontox
dose
compound
shown
activ
protect
chimera
infect
lethal
dose
p
aeruginosa
graft
site
tissu
clinic
util
glycyrrhizin
burn
wound
infect
sever
burn
patient
detail
toxicolog
test
requir
glycyrrhizin
direct
action
growth
p
aeruginosa
therefor
protect
effect
glycyrrhizin
graft
site
pseudomon
infect
chimera
must
display
host
antibacteri
function
influenc
glycyrrhizin
previou
murin
studi
glycyrrhizinassoci
improv
antimicrobi
peptid
product
shown
key
protect
sever
burn
mice
pseudomon
wound
infect
import
skin
antimicrobi
peptid
invas
pathogen
wound
tissu
welldescrib
howev
antimicrobi
peptid
produc
skin
tissu
surround
burn
wound
small
number
pathogen
invad
burn
wound
spread
easili
whole
bodi
skin
antimicrobi
peptid
produc
tissu
surround
burn
area
mice
treat
glycyrrhizin
sinc
glycyrrhizin
stimul
activ
antimicrobi
peptid
product
skin
keratinocyt
glycyrrhizin
may
improv
peptid
product
keratinocyt
indirectli
imc
identifi
murin
effector
cell
burnassoci
impair
peptid
product
human
studi
imc
identifi
cell
inhibit
peptid
product
skin
keratinocyt
human
antimicrobi
peptid
produc
unburn
skin
tissu
transwellcultur
syngen
cell
transwellcultur
effect
glycyrrhizin
improv
peptid
product
test
result
peptid
produc
transwellcultur
supplement
glycyrrhizin
subsequ
releas
imc
shown
inhibitori
peptid
product
skin
keratinocyt
cytokin
produc
imc
treat
glycyrrhizin
fact
strongli
suggest
inhibitori
effect
glycyrrhizin
product
imc
may
import
antipseudomon
activ
compound
glycyrrhizin
suppress
cytokin
product
imc
known
recent
studi
indic
glycyrrhizin
bind
glucocorticoidlik
receptor
mobil
group
box
protein
enhanc
region
gene
inhibit
glucocorticoid
progesteron
estrogen
cell
stimul
inflammatori
mediat
bind
glycyrrhizin
glucocorticoidlik
receptor
may
result
inhibit
gene
activ
phosphoryl
casein
kinas
protein
kinas
c
promot
releas
inflammatori
cytokin
howev
phosphoryl
inhibit
glycyrrhizin
bind
inhibitori
effect
glycyrrhizin
transcript
factor
may
involv
control
cytokin
product
imc
furthermor
inhibitori
effect
glycyrrhizin
activ
nfkb
mapk
includ
junk
erk
monocytesmacrophag
demonstr
acut
inflammatori
respons
activ
nfkb
mapk
import
product
increas
product
requir
activ
molecular
mechan
influenc
glycyrrhizin
may
also
involv
suppress
cytokin
product
imc
analyt
studi
requir
imc
may
function
suppress
burnassoci
inflamm
product
suggest
time
cours
burn
wound
heal
may
influenc
cell
experi
imc
shown
suppress
host
antibacteri
defens
product
glycyrrhizin
improv
host
antibacteri
resist
inhibit
product
imc
determin
wound
heal
influenc
glycyrrhizin
treatment
studi
requir
figur
resist
cirradi
nodscid
mice
treat
antiamp
igg
p
aeruginosa
skin
infect
cirradi
nodscid
mice
treat
sc
solid
circl
mice
without
antimurin
amp
igg
open
circl
mice
infect
id
b
c
p
aeruginosa
tif
